Selling Protection or Pushing Products? Inside India’s Growing Insurance Mis-Selling Debate

▴ India’s Growing Insurance Mis-Selling Debate
India’s insurance sector has the scale, capital, and opportunity to play a defining role in the country’s economic future.

India’s insurance industry is enjoying one of its most profitable phases in recent memory. Balance sheets are healthier, earnings are growing at double-digit rates, and insurers are reporting strong year-on-year performance across life and non-life segments. Yet beneath this glossy financial surface lies an uncomfortable truth that the country’s insurance regulator has chosen to confront head-on. Even as profits climb, public trust remains fragile, insurance penetration refuses to move, and mis-selling continues to cast a long shadow over the sector’s credibility. This widening gap between financial success and consumer confidence has prompted the Insurance Regulatory and Development Authority of India to issue a clear message that growth without ethics is unsustainable.

Mis-selling, in simple terms, refers to the sale of insurance products without proper disclosure, transparency, or suitability assessment. It occurs when policies are pushed aggressively without explaining exclusions, charges, lock-in periods, or long-term implications, or when products are sold to customers for whom they are plainly unsuitable. In India, this problem is neither new nor marginal. It has followed the sector for years, evolving with each new product launch, distribution channel, and sales incentive structure. What is striking now is the regulator’s firm acknowledgement that mis-selling remains a “significant concern” even as the industry posts record profits.

The regulator’s latest annual assessment calls for deeper introspection. Insurers have been asked to conduct detailed root-cause analyses to understand why mis-selling continues despite years of guidelines, training programs, and customer protection frameworks. This shift in tone matters. It signals that surface-level compliance and reactive damage control are no longer enough. The regulator wants insurers to examine their own systems, incentives, and culture to identify what truly drives unethical sales practices.

This regulatory push comes at a time when insurance penetration in India has stagnated. Overall insurance penetration stood at 3.7 per cent in FY25, unchanged from the previous year. Life insurance penetration slipped slightly to 2.7 per cent, while non-life insurance penetration remained flat at 1 per cent. These numbers tell a sobering story. In a country with a large population, rising incomes, and increasing awareness of health and financial risks, insurance coverage should be expanding steadily. Instead, it has hit a plateau. One of the key reasons is trust. When consumers hear stories of denied claims, misunderstood policies, or policies sold under pressure, hesitation replaces confidence.

The contradiction is stark. While insurance reach remains limited, industry profits are soaring. In FY25, the life insurance sector reported an impressive year-on-year profit growth of over 18 per cent, touching more than ₹56,000 crore. Non-life insurers did even better, posting nearly 30 per cent growth with profits exceeding ₹13,000 crore. Out of 25 life insurers operating during the year, 18 reported profits. The state-owned giant recorded a substantial rise in earnings, while private insurers collectively showed strong gains as well. These figures highlight the commercial strength of the sector, but they also raise a critical question. If profitability is rising so sharply, why is consumer participation not keeping pace?

Mis-selling offers part of the answer. Aggressive sales may boost short-term revenue, but they damage long-term relationships. A customer who feels misled is unlikely to buy another policy, recommend insurance to others, or view insurers as reliable partners in times of need. In a market like India, where financial literacy varies widely and insurance products are often complex, the responsibility on insurers is even greater. When that responsibility is compromised, the cost is paid in lost trust and stalled growth.

The regulator’s insistence on root-cause analysis is therefore timely. It pushes insurers to look beyond individual agents or isolated complaints and examine structural issues. Sales incentive models that reward volume over suitability are a major contributor. When agents and intermediaries are pressured to meet targets linked closely to commissions and bonuses, ethical considerations can take a back seat. Product complexity is another factor. Policies packed with fine print, riders, and conditional benefits create room for misinterpretation and selective disclosure. Weak training, especially in fast-growing distribution channels, further compounds the problem.

Another area of concern is the mismatch between products and customer needs. Many policies are sold as investment substitutes rather than protection tools, leading customers to expect guaranteed returns or liquidity that the product was never designed to offer. When expectations clash with reality, dissatisfaction is inevitable. The regulator has therefore advised insurers to strengthen product suitability assessments, ensuring that the right product reaches the right customer at the right time.

Distribution channels also come under scrutiny. India’s insurance market now spans traditional agents, bancassurance partnerships, corporate brokers, digital platforms, and direct-to-consumer models. Each channel has its own dynamics and risks. The regulator’s call for channel-specific controls acknowledges that a one-size-fits-all approach to compliance will not work. What is required is tailored oversight that reflects how each channel operates, how customers interact with it, and where mis-selling risks are most likely to arise.

Equally important is the handling of complaints. The regulator has urged insurers to adopt structured plans for addressing mis-selling grievances, backed by periodic root-cause reviews. This moves complaint management from a reactive exercise to a learning process. Complaints are no longer seen merely as customer service issues but as signals of deeper systemic problems. When analysed properly, they can reveal patterns that point to flawed sales practices, misleading communication, or inadequate disclosures.

The broader implication of this regulatory stance extends beyond compliance. It speaks to the future shape of India’s insurance market. Sustainable growth will depend less on aggressive selling and more on building long-term relationships grounded in transparency and trust. In an era where consumers are more informed and vocal, reputational damage travels fast. Social media, online reviews, and consumer forums amplify negative experiences, making it harder for insurers to hide behind fine print or technicalities.

From a policy perspective, addressing mis-selling is also essential for financial inclusion. Insurance is a cornerstone of economic security, protecting families from health shocks, income loss, and unforeseen events. When mis-selling erodes confidence, it discourages first-time buyers, especially among lower-income and rural populations. This undermines national goals of expanding insurance coverage and building a resilient financial system.

The regulator’s intervention should therefore be seen as an opportunity rather than a constraint. Insurers that take this moment seriously can differentiate themselves in a crowded market. Clear communication, simplified products, ethical sales practices, and robust grievance redressal mechanisms can become competitive advantages. Trust, once earned, translates into loyalty, renewals, and organic growth.

There is also a strong case for rethinking how success is measured within insurance companies. Profit growth is important, but it should not be the sole benchmark. Metrics related to customer satisfaction, persistency ratios, complaint resolution, and suitability outcomes deserve equal attention. Aligning internal incentives with these broader goals can help shift behaviour across the organisation.

Technology can play a constructive role as well. Digital sales journeys, recorded consent, standardised benefit illustrations, and data-driven suitability checks can reduce scope for mis-selling. However, technology is not a cure-all. Without the right intent and governance, even digital platforms can be misused. The emphasis must remain on ethics and accountability.

The regulator’s observations also raise questions about the role of financial education. While insurers must act responsibly, consumers need better understanding of insurance basics. Clearer disclosures, plain-language policy documents, and widespread awareness campaigns can empower buyers to ask the right questions. An informed customer is the strongest defence against mis-selling.

As India’s insurance industry stands at this crossroads, the message from the regulator is unambiguous. Profitability achieved at the cost of consumer trust is fragile. The sector’s impressive financial performance in FY25 shows what is possible, but stagnant penetration highlights what is missing. The gap between these two realities is trust, and mis-selling sits at the heart of that gap.

If insurers respond with genuine reform, the outcome could be transformative. A market built on transparency and suitability would attract more first-time buyers, deepen coverage, and sustain growth over the long term. If the warnings are ignored, however, the consequences may be harsher regulation, reputational damage, and a slower path to expansion.

In the end, insurance is a promise. It is a commitment to stand by individuals and families when they are most vulnerable. When that promise is compromised through mis-selling, the damage goes beyond financial loss. It erodes faith in an entire system. The regulator’s call for introspection is therefore not just about correcting sales practices. It is about restoring the moral foundation on which the insurance business rests.

India’s insurance sector has the scale, capital, and opportunity to play a defining role in the country’s economic future. Whether it can do so with integrity will determine if rising profits translate into lasting public trust or remain numbers on a balance sheet disconnected from the lives they are meant to protect.

Tags : #InsuranceMisSelling #IRDAI #PolicyholderProtection #InsuranceReforms #ConsumerTrust #EthicalSelling #InsuranceIndia #FinancialInclusion #MissellingDebate #CustomerFirst #smitakumar #medicircle

Related Stories

Loading Please wait...

-Advertisements-






Trending Now

Healthcare Leaders Share Industry Insights Shaping IndiaJuly 04, 2026
Warning Signs Your Body Gives Before Serious IllnessJuly 04, 2026
Diabetes Prevention Tips for Indians: A Practical GuideJuly 03, 2026
Superbugs and Global Health: India's Growing AMR CrisisJuly 03, 2026
Navigating a New Cancer Diagnosis: Oncologists & Pathways July 02, 2026
Skin Allergies in the Monsoon: Common Triggers and TreatmentsJuly 02, 2026
The Growing Problem of Antibiotic Resistance in IndiaJuly 02, 2026
Future of Healthcare in India: Doctors on AI and CareJuly 02, 2026
High Blood Pressure: Causes, Symptoms and Prevention GuideJuly 02, 2026
CARE Hospitals Celebrates National Doctors' Day, Honours Doctors for Their Commitment to Saving LivesJuly 01, 2026
Ancient Wisdom Meets Modern Science at Happiest Health’s ‘Ayurveda & Gut’ EventJuly 01, 2026
Estrogen Replacement Therapy Market Size to Reach USD 19.4 Billion by 2034 at a 5.7% CAGR from 2026 to 2034July 01, 2026
MGM Healthcare and MGM Cancer Institute announced an exclusive Master Health and Vaccination Package for Blood Donors.July 01, 2026
QR678® Enters European Market with Germany as Strategic Launchpad for QR678 X-PRO®July 01, 2026
Patient Experience in Healthcare: Why It Matters in IndiaJuly 01, 2026
Antibiotic Resistance in India: Causes, Risks and SolutionsJuly 01, 2026
The Truth About Antibiotics: Why You Should Never Self-Medicate July 01, 2026
The Role of Microbiome in Gut Health and ImmunityJuly 01, 2026
Understanding Autoimmune Diseases: Why Your Body Attacks Itself July 01, 2026
Thyroid Cancer: Early Signs, Diagnosis, and Treatment in IndiaJuly 01, 2026